-
Insmed (INSM
+18%) announced stability studies for IPLEX(TM), the company's once-daily
treatment for children with short stature associated with severe primary IGF-I
deficiency, indicate that IPLEX is highly stable under common household storage
conditions. Shares recently traded at 1.03, well above the 0.88 close on
Wednesday
احد منتجات الشركة الخاص بالاطفال يعطى نتائج جيدة
بريماركت = 1,03